Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
19.47B
Market cap19.47B
Price-Earnings ratio
-6.02
Price-Earnings ratio-6.02
Dividend yield
Dividend yield
Average volume
10.53M
Average volume10.53M
High today
$49.88
High today$49.88
Low today
$47.91
Low today$47.91
Open price
$48.34
Open price$48.34
Volume
7.23M
Volume7.23M
52 Week high
$59.55
52 Week high$59.55
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

Moderna(MRNA) stock is priced at $48.57, giving the company a market capitalization of 19.47B. It carries a P/E multiple of -6.02.

On 2026-05-17, Moderna(MRNA) stock moved within a range of $47.91 to $49.88. With shares now at $48.57, the stock is trading +1.4% above its intraday low and -2.6% below the session's peak.

Trading volume for Moderna(MRNA) stock has reached 7.23M, versus its average volume of 10.53M.

Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $59.55 and a low of $22.28.

Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $59.55 and a low of $22.28.

MRNA News

Simply Wall St 5h
Is Moderna Quietly Recasting Its mRNA Platform From Pandemic Play to Broad Vaccine Franchise?

In recent months, Moderna reported strong Phase 3 data showing its mRNA-1010 flu vaccine outperformed standard shots in adults 50 and older, while publishing ea...

Is Moderna Quietly Recasting Its mRNA Platform From Pandemic Play to Broad Vaccine Franchise?
TipRanks 1d
Moderna Stock Stumbles as Vaccine Hype Meets Reality

Moderna ( (MRNA) ) has fallen by -7.26%. Read on to learn why. Claim 55% Off TipRanks Unlock hedge fund-level data and powerful investing tools for smarter, sha...

Simply Wall St 1d
Assessing Moderna Valuation After Flu Vaccine Data And Hantavirus Program Interest

Moderna (MRNA) is back in focus after fresh clinical data showed its mRNA 1010 flu shot outperformed standard vaccines in adults over 50. Early hantavirus work...

Assessing Moderna Valuation After Flu Vaccine Data And Hantavirus Program Interest

Analyst ratings

73%

of 26 ratings
Buy
15.4%
Hold
73.1%
Sell
11.5%

More MRNA News

Investing.com 2d
Hantavirus: Is there a risk of another pandemic? - Investing.com

...

Hantavirus: Is there a risk of another pandemic? - Investing.com
TipRanks 2d
Moderna and Merck Push Personalized Lung Cancer Vaccine Into Phase 3

Moderna (MRNA) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions D...

Simply Wall St 4d
Moderna’s TIME Ranking And Combo Vaccine Approval Reshape Growth Question

Moderna (NasdaqGS:MRNA) ranked no. 1 on TIME's 2026 World's Most Impactful Companies list. The company received European approval for mCOMBRIAX, its first comb...

Moderna’s TIME Ranking And Combo Vaccine Approval Reshape Growth Question
Barron's 5d
Why Moderna Is Still the Ultimate Stock Hedge Against Any Outbreak

Biotech and Pharma Why Moderna Is Still the Ultimate Stock Hedge Against Any Outbreak In this article MRNA SPX MRK Moderna’s Spikevax Covid vaccine has been a m...

Why Moderna Is Still the Ultimate Stock Hedge Against Any Outbreak
TipRanks 6d
Moderna gains 9% as U.S. citizen tests positive for hantavirus

Shares of Moderna (MRNA) are up nearly 9% in premarket trading as the company evaluates potential treatments targeting hantavirus. According to reports, a U.S....

The Motley Fool 6d
Stock Market Today, May 11: Chipmakers Drive Midday Gains Despite Oil Concerns

As of midday, the S&P 500 (^GSPC +0.17%) rose 0.34% to 7,424.04, the Nasdaq Composite (^IXIC +0.14%) added 0.38% to 26,346.51. The Dow Jones Industrial Average...

Stock Market Today, May 11: Chipmakers Drive Midday Gains Despite Oil Concerns
Nasdaq 6d
Biotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone?

Key Points Moderna, Novavax, and Inovio have all seen their stocks surge due to concerns about hantavirus. Moderna is in the early stages of developing treatm...

Biotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone?

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.